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Background
Recent studies have conﬁ  rmed that 
acute HIV infection results in a 
rapid and profound loss of memory 
CD4+CCR5+ T cells within the ﬁ  rst few 
weeks of infection [1,2]. Since most of 
these cells reside in the intestinal tract, 
profound CD4+ T cell depletion occurs 
in the intestine within days of infection, 
whereas peripheral lymphoid tissues 
such as blood and lymph nodes, which 
harbor mainly naïve CD4+ T cells, are 
less severely affected. These studies 
conﬁ  rmed earlier reports in macaques 
infected with simian immunodeﬁ  ciency 
virus (SIV) [3] and demonstrated that 
primary HIV infection results in rapid 
and dramatic losses of the majority of 
the CD4+ T cells in the body. However, 
profound losses can only be detected 
when examining mucosal tissues (i.e., 
the intestine). Recognition of the 
mucosal immune system as a principal 
target of early HIV infection constitutes 
a fundamental change in our 
understanding of HIV pathophysiology, 
with potential implications for 
therapeutic monitoring and vaccine 
development [4]. 
New Studies in HIV-Infected 
Patients
Clearly, the massive loss of intestinal 
memory CD4+ T cells imparts profound 
disturbances in mucosal immunity. 
However, since mucosal tissues are at 
best inconvenient to sample, little is 
known regarding the impact of the loss 
of this important T cell subset on host 
immunity or disease progression. In 
addition, the potential for antiretroviral 
therapy (ART) to restore mucosal 
CD4+ T cells has been difﬁ  cult to 
assess, particularly in acute infection. 
In a new paper by Mehandru et al. 
[5], lymphocyte populations from the 
intestine and peripheral blood were 
obtained from a relatively large cohort 
(n = 54) of HIV-infected patients soon 
after infection. These samples were 
examined and compared with the 
same samples obtained from HIV-
uninfected volunteers to determine 
whether early therapeutic intervention 
could restore intestinal CD4+ T cells 
to baseline levels. Prior to this study, 
few had examined the effects of ART 
on HIV-infected humans or SIV-
infected macaques, particularly in 
early infection. A study by Guadalupe 
et al. had suggested near complete 
restoration of mucosal CD4+ T cells in 
HIV-infected patients when therapy was 
initiated early, but only three acutely 
infected patients were examined [6]. 
Studies of SIV-infected macaques 
also suggested that initiating therapy 
early could result in near complete 
restoration of mucosal CD4+ T cells, but 
again, few animals were examined [7]. 
In contrast, Mehandru et al. recently 
reported a lack of intestinal CD4+ T 
cell repopulation in patients on ART, 
but this was a cross-sectional study and 
only eight patients were examined 
[2]. In summary, although CD4+ T 
cells in the peripheral blood have 
been reported to fully reconstitute in 
patients on ART, there is considerable 
controversy regarding the capacity for 
restoration of intestinal CD4+ T cells, 
particularly for patients treated in the 
early stages of infection. This is more 
than an academic issue, since acutely 
infected patients are seldom started on 
ART. Treatment guidelines generally 
recommend waiting to initiate therapy 
until blood CD4 cell counts have 
fallen, in order to reduce the risk of 
medication side effects as well as the 
potential for selecting drug-resistant 
HIV. 
In the current paper, 54 patients 
in the acute stage of HIV infection 
were examined and compared with 
18 uninfected volunteers. Of the 
acutely infected patients, 14 were 
examined only prior to ART, 18 were 
examined prior to ART and then 
sequentially through one to three 
years of uninterrupted therapy, and 
22 were examined cross-sectionally 
at time points ranging from less than 
one year to seven years after starting 
ART. Although partial restoration of 
mucosal CD4+ T cells was observed on 
ART, the results clearly demonstrate 
that restoration is only partial in the 
majority of patients compared to 
uninfected controls, even after several 
years of “fully suppressive” ART. In 
addition, these studies demonstrate 
increased levels of activation in the 
intestinal immune system of patients on 
ART, even though immune activation 
in the peripheral blood often returns 
to baseline levels. The combined results 
of this new study suggest that ongoing 
viral replication and CD4+ T cell 
destruction occur in the intestine of 
patients on ART, despite what appears 
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to be complete suppression of viral 
replication in the blood. 
Limitations of HIV Studies 
Given the enormous practical 
challenges involved in obtaining 
mucosal biopsies from acutely infected 
patients, the work presented here is 
certainly valuable. However, a few 
limitations are inherent in interpreting 
the results and especially in comparing 
these data to those from SIV-infected 
macaques. First, neither pre-infection 
CD4 levels nor the exact timing of the 
initial infection were known, as patients 
were deemed to be in acute stage 
of infection based on viremia in the 
face of negative serology. In contrast, 
studies of SIV-infected macaques were 
based on restoration to pre-inoculation 
CD4 levels. Furthermore, therapy in 
the macaques was initiated at six weeks 
of infection [7], which is likely much 
earlier than the human patients in 
the current study. Second, the current 
study examined rectum/colon CD4+ 
T cells, whereas macaque studies are 
usually performed using samples from 
the jejunum. The rectum/colon is a 
mix of immune inductive (organized 
lymphoid tissues) and effector sites 
(diffuse lamina propria) whereas the 
jejunum contains almost no immune 
inductive sites. This is reﬂ  ected in 
the lymphoid composition of each 
tissue: the jejunum contains mostly 
memory CD4+ T cells, while the colon 
contains a larger proportion of naïve 
CD4+ T cells. This makes it difﬁ  cult 
to extrapolate comparisons of T cell 
subsets from these disparate sites. 
Third, the percentages of “activated” T 
cell subsets remaining after treatment 
need to be interpreted with caution, 
as these are “snapshot” data observed 
during what is now believed to be a 
very dynamic process. For example, 
detection of increased percentages 
of “activated” CD4+ T cells in a tissue 
that has undergone massive CD4+ T 
cell depletion could be interpreted 
either as an immune response to 
the infection or as a selective loss of 
“resting” CD4+ T cells. However, given 
that the study also found that higher 
activation levels were associated with 
poorer mucosal reconstitution, the 
more logical interpretation is that 
HIV infection results in continual 
activation, turnover, and destruction 
of intestinal CD4+ T cells. Finally, the 
low level of infected cells detected in 
the intestine of patients on ART should 
be interpreted with caution, as the 
conclusion was based on small biopsy 
samples taken from the largest immune 
organ in the body. Detecting even a 
small number of infected cells in these 
pinch biopsies could reﬂ  ect a very large 
number of infected cells throughout 
the intestine.
Conclusions and Clinical 
Implications
In conclusion, the ﬁ  ndings reported 
by Mehandru et al. indicate that most 
patients who initiate therapy as early 
as possible after HIV infection still do 
not experience complete restoration 
of intestinal CD4+ T cells to baseline 
levels, regardless of the duration of 
therapy. Instead, HIV infection results 
in a continuous state of activation in 
the intestinal immune system that is 
not reﬂ  ected in peripheral lymphoid 
tissues. Combined, the data provide 
evidence that intestinal inﬂ  ammation 
and continual infection, destruction, 
and turnover of CD4+ T cells occur 
in patients on ART, suggesting that 
the major battle against HIV occurs 
in sequestered mucosal tissue sites. 
This important observation suggests 
a number of potential therapeutic 
strategies for further research; for 
example, the investigation of drugs 
with better intestinal tissue distribution 
and perhaps the exploration of 
mechanisms to reduce immune 
activation in mucosal tissues to more 
effectively combat HIV infection.  
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